Balyasny Asset Management LLC Tricida, Inc. Transaction History

Balyasny Asset Management LLC

6 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2022 Nov 14, 2022	BUY	$8.51 - $13.6 $222,196 - $355,096	26,110 Added 4.08%	665,903 $6.98 Million
Q2 2022 Aug 15, 2022	BUY	$7.31 - $11.85 $192,194 - $311,560	26,292 Added 4.29%	639,793 $6.19 Million
Q1 2022 May 16, 2022	BUY	$7.35 - $10.63 $2.73 Million - $3.94 Million	370,858 Added 152.84%	613,501 $5.04 Million
Q4 2021 Feb 14, 2022	BUY	$4.19 - $9.56 $1.02 Million - $2.32 Million	242,643 New	242,643 $2.32 Million
Q3 2018 Nov 14, 2018	SELL	$22.5 - $39.35 $388,125 - $678,787	-17,250 Closed	0 $0

Q2 2018 Aug 14, 2018	BUY	$26.0 - $29.9 $448,500 - $515,775	17,250 New	17,250 $516,000

30K

124K

46.5K

Ticker TCDA
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 55,668,900
Market Cap $557K
Description
Tricida, Inc. operates as a pharmaceutical company. It focuses on the development and commercialization of veverimer (TRC101), a non-absorbed orally-administered polymer that has completed Phase III trial to treat metabolic acidosis in patients with chronic kidney disease by binding and removing acid from the gastrointestinal track. The company ...

Get notified when there are updates to the investment portfolio of Balyasny Asset Management LLC, based on Form 13F filings with the SEC.

Stay updated on Balyasny Asset Management LLC with notifications on news.